Plain-English translation of NCT06793449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer approach called BCMA CAR-T cell therapy works as well as the standard stem cell transplant for treating newly diagnosed multiple myeloma. Both groups start with the same chemotherapy combination, but then one group receives the new cell therapy while the other receives the traditional stem cell transplant. The goal is to see if this new treatment can help patients live longer without their cancer coming back.
Stem cell transplants have been the standard treatment for multiple myeloma for many years, but they can be hard on the body and don't work for everyone. Researchers want to know if this newer cell-based therapy could be just as effective or better, while potentially being easier for patients to tolerate.
You likely qualify if…
You likely don't qualify if…
You would receive 3–4 cycles of chemotherapy first, then be randomly assigned to either the new cell therapy group or the stem cell transplant group. If assigned to cell therapy, you'd receive conditioning treatment followed by infusion of your own modified immune cells, then maintenance therapy for at least 2 years. If assigned to stem cell transplant, you'd receive high-dose chemotherapy followed by transplantation, then maintenance therapy for at least 2 years. Throughout the study, you'll have regular clinic visits, blood tests, and imaging to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China